Literature DB >> 2039760

Dopamine and norepinephrine activity in schizophrenia. An integrative perspective.

D P van Kammen1, M Kelley.   

Abstract

The dopamine (DA) hypothesis of schizophrenia stated that increased DA activity is the primary cause of schizophrenia. Recently, even though increased DA activity is in fact involved in psychotic symptoms and antipsychotic drug response, it has become clear that decreased DA activity is present in remitted and chronic states and may relate to deficit symptoms and cortical lesions. In addition, the norepinephrine (NE) system seems to be involved in symptomatology, antipsychotic drug response, course, and outcome in schizophrenia. This review supports the hypothesis that a disturbance in DA and NE activity regulates schizophrenic behavior. A plethora of DA- and NE-related findings in schizophrenic patients are reviewed in relationship to each other according to basic science data and to presently entertained hypotheses, with emphasis on a neural developmental disturbance interacting with a genetic predisposition shaped by environmental factors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039760     DOI: 10.1016/0920-9964(91)90032-m

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  17 in total

Review 1.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

2.  The enzymatic activities of brain catechol-O-methyltransferase (COMT) and methionine sulphoxide reductase are correlated in a COMT Val/Met allele-dependent fashion.

Authors:  Jackob Moskovitz; Consuelo Walss-Bass; Dianne A Cruz; Peter M Thompson; Jenaqua Hairston; Marco Bortolato
Journal:  Neuropathol Appl Neurobiol       Date:  2015-05-02       Impact factor: 8.090

3.  Cumulative stress pathophysiology in schizophrenia as indexed by allostatic load.

Authors:  Katie L Nugent; Joshua Chiappelli; Laura M Rowland; L Elliot Hong
Journal:  Psychoneuroendocrinology       Date:  2015-06-21       Impact factor: 4.905

4.  Blood biogenic amines during clozapine treatment of early-onset schizophrenia.

Authors:  E Schulz; C Fleischhaker; H W Clement; H Remschmidt
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 5.  A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications.

Authors:  George E Jaskiw; Anand P Popli
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

6.  Manic symptom severity correlates with COMT activity in the striatum: A post-mortem study.

Authors:  Marco Bortolato; Consuelo Walss-Bass; Peter M Thompson; Jackob Moskovitz
Journal:  World J Biol Psychiatry       Date:  2016-07-26       Impact factor: 4.132

Review 7.  Adrenergic targets for the treatment of cognitive deficits in schizophrenia.

Authors:  Amy F T Arnsten
Journal:  Psychopharmacology (Berl)       Date:  2003-12-19       Impact factor: 4.530

8.  Visual discrimination among patients with depression and schizophrenia and healthy individuals using semiquantitative color-coded fast spin-echo T1-weighted magnetic resonance imaging.

Authors:  Makoto Sasaki; Eri Shibata; Kotaro Ohtsuka; Jin Endoh; Kohsuke Kudo; Shinsuke Narumi; Akio Sakai
Journal:  Neuroradiology       Date:  2009-09-15       Impact factor: 2.804

9.  CSF levels of diazepam-binding inhibitor correlate with REM latency in schizophrenia, a pilot study.

Authors:  D P van Kammen; A Guidotti; T Neylan; P Guarneri; M E Kelley; J Gurklis; M W Gilbertson; J L Peters; E Costa
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

10.  Regulation of cortical and peripheral GCH1 expression and biopterin levels in schizophrenia-spectrum disorders.

Authors:  James D Clelland; Laura L Read; Jennifer Smeed; Catherine L Clelland
Journal:  Psychiatry Res       Date:  2018-02-08       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.